Krassas, G E <br/><br/>
Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues.  [electronic resource] 

 -  Thyroid : official journal of the American Thyroid Association  Dec 2001 
 - 1115-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1050-7256 
<br/><br/><label>Standard No.: </label>10.1089/10507250152740957  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Cell Adhesion Molecules--blood<br/>Eye Diseases--blood<br/>Female<br/>Hormones--therapeutic use<br/>Humans<br/>Intercellular Adhesion Molecule-1--blood<br/>Interleukin 1 Receptor Antagonist Protein<br/>Male<br/>Middle Aged<br/>Octreotide--therapeutic use<br/>Peptides, Cyclic--therapeutic use<br/>Prospective Studies<br/>Sialoglycoproteins--blood<br/>Solubility<br/>Somatostatin--analogs & derivatives<br/>Thyroid Diseases--complications<br/>Tumor Necrosis Factor-alpha--analysis<br/>Vascular Cell Adhesion Molecule-1--blood